Rapport Therapeutics, Inc. Common Stock
HealthcareNASDAQ:RAPP · NASDAQ Global Market
+$3.19 today
Vol 0.25M · Avg 0.32M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.0%
avg 8.1%
ROIC
-25.2%
avg -27.9%
ROA
-21.8%
avg -25.7%
Analysis
ROA is currently the strongest return metric at -21.8% versus its period average of -25.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Abraham N. Ceesay | Chief Executive Officer, President, Treasurer & Director | $1.11M | — | 48 | $22,829.00 | 0.06% |
Jeffrey Sevigny | Chief Medical Officer | $1.04M | — | 56 | $130,000.00 | 0.36% |
Troy A. Ignelzi | Chief Financial Officer | $795,366.00 | — | 58 | $148,000.00 | 0.41% |
Cheryl Gault | Chief Operating Officer | $281,110.00 | — | 46 | $162,753.00 | 0.45% |
Steven Paul | Founder & Independent Chairman | $44,000.00 | — | 75 | $15,200.00 | 0.04% |
Brian Corcoran | Controller | — | — | — | — | — |
Arnold R. Gammaitoni | Senior Vice President of Medical Affairs | — | — | 59 | — | — |
David Bredt | Founder & Chief Scientific Officer | — | — | 60 | $393,075.00 | 1.08% |
Swamy Yeleswaram | Chief Development Officer | — | — | 62 | $246,426.00 | 0.68% |
Julie DiCarlo | Head of Communications & Investor Relations | — | — | — | — | — |
Karina Chmielewski | Chief Information Officer & Head of Operations | — | — | — | — | — |
Kathleen A. Wilkinson | Chief People Officer | — | — | 54 | $148,000.00 | 0.41% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$1.61M
Sells
59
$42.38M
Net Sentiment
$40.78M
Net selling
Most Active
Ceesay Abraham
24 transactions
1–10 of 63
Analysis
Insiders reported 4 buys worth $1.61M and 59 sells worth $42.38M over the last 12 months. That adds up to net selling of $40.78M. Ceesay Abraham was the most active insider with 24 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Oculis Holding AG
NASDAQ:OCS
$634.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
Who manages RAPP?
Rapport Therapeutics, Inc. Common Stock (RAPP) lists 12 active executives. The top listed executive is Brian Corcoran, Controller.
Are RAPP insiders buying or selling?
Recent insider activity shows net buying of $15.45M.
Explore More
Continue the stock analysis
Jump to another research area for this company.